Phase 2, Open-Label, Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer

Study Name:
A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 subjects with KRASG12C mutant NSCLC that have not been exposed to prior therapy with KRASG12C inhibitors and/or SHP2 inhibitors.

Study Dates:
October 1, 2021 - January 31, 2024

Study Design:
Controlled Design

Study Location:
Nationwide

Lead Institution:
Revolution Medicines, Inc.

Register for Trial
Freedom From Smoking Clinic
, | Oct 25, 2021
Lung Mind Alliance Convening
, | Dec 08, 2021